The effects of histamine and leukotriene receptor antagonism on nasal mannitol challenge in allergic rhinitis

British Journal of Clinical Pharmacology

Volumn 55, Issue 6, 2003, Pages 639-642

  Lee, Daniel K C ^a   Haggart, Kay ^a   Currie, Graeme P ^a   Anderson, Sandra D ^b   Lipworth, Brian J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Allergic rhinitis; Desloratadine; Mannitol; Montelukast; Nasal hyper reactivity

Indexed keywords

ANTIHISTAMINIC AGENT; DESLORATADINE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MANNITOL; MONTELUKAST; PLACEBO;

ADULT; ALLERGIC RHINITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; NOSE AIRFLOW; NOSE MUCOSA; PRIORITY JOURNAL; PROVOCATION TEST;

ACETATES; ADULT; CROSS-OVER STUDIES; DIURETICS, OSMOTIC; DOUBLE-BLIND METHOD; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; INSPIRATORY CAPACITY; LORATADINE; MANNITOL; MIDDLE AGED; NASAL PROVOCATION TESTS; QUINOLINES; RHINITIS, ALLERGIC, SEASONAL;

EID: 0038804144     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01807.x     Document Type: Article

References (16)

1. Malm L, Gerth vW, Bachert C. Guidelines for nasal provocations with aspects on nasal patency, airflow, and airflow resistance. International Committee on Objective Assessment of the Nasal Airways, International Rhinologic Society. Rhinology 2000; 38: 1-6.
2. Cockcroft DW. How best to measure airway responsiveness. Am J Respir Crit Care Med 2001; 163: 1514-1515.
3. Anderson SD, Brannan J, Spring J, et al. A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol. Am J Respir Crit Care Med 1997; 156: 758-765.
4. Koskela H, Di Sciascio MB, Anderson SD, et al. Nasal hyperosmolar challenge with a dry powder of mannitol in patients with allergic rhinitis. Evidence for epithelial cell involvement. Clin Exp Allergy 2000; 30: 1627-1636.
5. Litvyakova LI, Baraniuk JN. Nasal provocation testing: a review. Ann Allergy Asthma Immunol 2001; 86: 355-364.
6. Agrawal DK. Pharmacology and clinical efficacy of desloratadine as an anti-allergic and anti-inflammatory drug. Expert Opin Invest Drugs 2001; 10: 547-560.
7. Henz BM. The pharmacologic profile of desloratadine: a review. Allergy 2001; 56(Suppl 65): 7-13.
8. Geha RS, Meltzer EO. Desloratadine: a new, nonsedating, oral antihistamine. J Allergy Clin Immunol 2001; 107: 751-762.
9. Bachert C. Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis. Allergy 2001; 56(Suppl 65): 14-20.
10. Lipworth BJ. Emerging role of antileukotriene therapy in allergic rhinitis. Clin Exp Allergy 2001; 31: 1813-1821.
11. Affrime M, Gupta S, Banfield C, Cohen A. A pharmacokinetic profile of desloratadine in healthy adults, including elderly. Clin Pharmacokinet 2002; 41(Suppl 1): 13-19.
12. Cheng H, Leff JA, Amin R, et al. Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. Pharm Res 1996; 13: 445-448.
13. Wilson AM, Sims EJ, Robb F, Cockburn WJ, Lipworth BJ. Peak inspiratory flow rate is more sensitive than acoustic rhinometry or rhinomanometry in detecting corticosteroid response with nasal histamine challenge. Rhinology 2002; in press.
14. Brannan JD, Anderson SD, Gomes K, King GG, Chan HK, Seale JP. Fexofenadine decreases sensitivity to and montelukast improves recovery from inhaled mannitol. Am J Respir Crit Care Med 2001; 163: 1420-1425.
15. Anderson SD, Brannan JD. Exercise-induced asthma: is there still a case for histamine? J Allergy Clin Immunol 2002; 109: 771-773.
16. Rafferty P, Beasley R, Holgate ST. The contribution of histamine to immediate bronchoconstriction provoked by inhaled allergen and adenosine 5′ monophosphate in atopic asthma. Am Rev Respir Dis 1987; 136: 369-373.